Document is current
Any future updates will be listed below
-
Authors
Bogsrud, Trond Velde https://orcid.org/0000-0002-9451-4648
Engelsen, Ola
Lu, Thuy Thu Thi
Stensvold, Andreas
Johnson, Derek R.
Burkett, Brian J.
Kendi, Ayse Tuba
Pandey, Mukesh K.
Sundset, Rune
Durski, Jolanta M.
-
Funding
Funding for this research was provided by:
Ostfold Hospital, Kalnes (Ostfold Hospital, Kalnes)
- License Information
-
More Information
Article History
Received: 21 August 2024
Accepted: 29 September 2024
First Online: 15 October 2024
Declarations
:
: The Norwegian Medical Products Agency approved the unapproved use of [<sup>177</sup>Lu]Lu-PSMA-I&T for treatment of renal cell carcinoma in the patient. The Institutional Review Board gave ethical approval of the experimental treatment. The patient gave a consent to the procedure.
: Written informed consent was obtained from the patient for publication of this case report and accompanying images.
: The authors have nothing to disclose / there is no conflict of interest.
